Fenben for humans is a medication that was first debuted in scientific trials some years ago for its cancer-fighting properties. The drug is typically used in animals to treat parasites (hookworms, whipworms, and some tapeworms) under the brand names of Pancur and Safe-Guard. Recently, the medication has gained popularity due to a well-known story of a man who successfully treated his small cell lung cancer with the drug.
The Joe Tippens Protocol is a method of treatment that involves combining a variety of anti-cancer foods with the administration of anthelmintic drugs such as fenbendazole. Since the patient’s case was publicized on social media platforms such as Twitter and Facebook, many patients have obtained information about this treatment and have subsequently self-administered fenbendazole to treat their cancer.
In a previous study, we showed that the addition of fenbendazole to human cancer cells caused microtubule depolymerization and induction of p53, a critical tumor suppressor. Additionally, fenbendazole disrupted glucose uptake into cancer cells by down regulation of GLUT transporters and hexokinase – a key glycolytic enzyme that most cancer cells require for their growth.
To determine whether fenbendazole would act as a radiosensitizer, we exposed EMT6 cells to graded doses of radiation either with and without 10 mM fenbendazole. Irradiated cells were assayed for survival using a colony formation assay, and results were compared to unirradiated cells. We found that fenbendazole did not significantly alter radiation-sensitivity in aerobic or hypoxic cultures. The chemical structure of fenbendazole resembles those of compounds that have been shown to act as radiosensitizers. fenben for humans